Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanCorporateVeterinaryHerbalTopicMedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceAdvanced therapiesCompliance and inspectionsData on medicinesClinical trialsInnovationResearch and developmentBiosimilarsSMEAntimicrobial resistanceMedicine shortagesBrexitQuality of medicinesGeneric and hybrid medicinesGovernanceEarly accessProduct informationFeesScientific adviceCorporateMedicines for use outside the EUMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorParallel distributionProcurementDiseases areaViral diseasesCancerImmune-system diseasesNeurodegenerative diseasesCardiovascular diseasesDiabetesHIV and AIDSTreatment of human immunodeficiency virus type 1 (HIV-1) infectionResponsible bodyCHMPCVMPPRACManagement BoardCOMPPDCOCMDhHMPCCATPatient safetyYesFiltersResults (3621) Sort byLast update date (new to old)Last update date (old to new)A-ZZ-AMonitoring of products originating from Japan for the possibility of radioactivity11 October 2023NewsMeeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 October 20236 October 2023NewsVeterinaryMedicinesEMA Management Board: highlights of October 2023 meeting6 October 2023NewsCorporateRevised transparency rules for the EU Clinical Trials Information System (CTIS)6 October 2023NewsEMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna5 October 2023NewsHumanMedicinesMeeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 September 202329 September 2023NewsHumanPharmacovigilanceReferralsEMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep28 September 2023NewsHumanMedicinesTowards a permanent collaboration framework for EMA and Health Technology Assessment bodies15 September 2023NewsHumanMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 202315 September 2023NewsHumanCOVID-19MedicinesReferralsSpikevax: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.514 September 2023NewsHumanCOVID-19MedicinesPrevious5678910111213Next
Monitoring of products originating from Japan for the possibility of radioactivity11 October 2023News
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 October 20236 October 2023NewsVeterinaryMedicines
EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna5 October 2023NewsHumanMedicines
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 September 202329 September 2023NewsHumanPharmacovigilanceReferrals
EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep28 September 2023NewsHumanMedicines
Towards a permanent collaboration framework for EMA and Health Technology Assessment bodies15 September 2023NewsHuman
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 202315 September 2023NewsHumanCOVID-19MedicinesReferrals
Spikevax: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.514 September 2023NewsHumanCOVID-19Medicines